GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biomark Diagnostics Inc (FRA:20B) » Definitions » Cyclically Adjusted Book per Share

Biomark Diagnostics (FRA:20B) Cyclically Adjusted Book per Share : €-0.01 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Biomark Diagnostics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Biomark Diagnostics's adjusted book value per share data for the fiscal year that ended in Mar. 2023 was €-0.009. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €-0.01 for the trailing ten years ended in Mar. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-06-09), Biomark Diagnostics's current stock price is € 0.13. Biomark Diagnostics's Cyclically Adjusted Book per Share for the fiscal year that ended in Mar. 2023 was €-0.01. Biomark Diagnostics's Cyclically Adjusted PB Ratio of today is .


Biomark Diagnostics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Biomark Diagnostics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomark Diagnostics Cyclically Adjusted Book per Share Chart

Biomark Diagnostics Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -0.01

Biomark Diagnostics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.01 - - -

Competitive Comparison of Biomark Diagnostics's Cyclically Adjusted Book per Share

For the Diagnostics & Research subindustry, Biomark Diagnostics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomark Diagnostics's Cyclically Adjusted PB Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Biomark Diagnostics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Biomark Diagnostics's Cyclically Adjusted PB Ratio falls into.



Biomark Diagnostics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biomark Diagnostics's adjusted Book Value per Share data for the fiscal year that ended in Mar. 2023 was:

Adj_Book=Book Value per Share /CPI of Mar. 2023 (Change)*Current CPI (Mar. 2023)
=-0.009/122.7021*122.7021
=-0.009

Current CPI (Mar. 2023) = 122.7021.

Biomark Diagnostics Annual Data

Book Value per Share CPI Adj_Book
201403 0.000 98.604 0.000
201503 0.002 99.789 0.002
201603 -0.007 101.054 -0.008
201703 -0.014 102.634 -0.017
201803 -0.009 105.004 -0.011
201903 -0.012 106.979 -0.014
202003 -0.004 107.927 -0.005
202103 -0.001 110.298 -0.001
202203 -0.006 117.646 -0.006
202303 -0.009 122.702 -0.009

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Biomark Diagnostics  (FRA:20B) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Biomark Diagnostics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Biomark Diagnostics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomark Diagnostics (FRA:20B) Business Description

Traded in Other Exchanges
Address
130 - 3851 Shell Road, Richmond, BC, CAN, V6X 2W2
Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early treatment for cancer. Its research and development are focused on the role that metabolomics plays in early cancer detection. It is currently focused on bringing its liquid biopsy-based cancer diagnostic tests and detection solution to commercialization.

Biomark Diagnostics (FRA:20B) Headlines

No Headlines